Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CTL 119

Drug Profile

CTL 119

Alternative Names: Anti-CD19 CAR-T cell therapy - Novartis/University of Pennsylvania; CTL119; huCART19; huCTL019

Latest Information Update: 09 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Pennsylvania
  • Developer Novartis; University of Pennsylvania
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Lymphoid leukaemia; Non-Hodgkin's lymphoma
  • No development reported B-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Multiple myeloma

Most Recent Events

  • 10 Jan 2023 University of Pennsylvania plans a phase I/II trial for Precursor cell lymphoblastic leukaemia-lymphoma (In infants, In children, In adolescents, In adults, Combination therapy) by January 2023 (Parenteral) (NCT05674175)
  • 10 Dec 2022 Safety and efficacy data from a phase I trial in Non-Hodgkin's lymphoma and Lymphoid leukaemia presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-2022)
  • 28 Dec 2021 No recent reports of development identified for clinical-Phase-Unknown development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Combination therapy, In children, Second-line therapy or greater) in USA (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top